# Rifaximin in Patients With Diabetic Gastroparesis

> **NCT04254549** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 5 (actual)

## Conditions studied

- Crohn Disease
- Diabetic Gastroparesis

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04254549
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-14
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-04-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor discontinued placebo. Unable to meet enrollment goals.
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254549, "Rifaximin in Patients With Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04254549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*